3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Leukemia, Myeloid, Chronic-Phase
14
Leukemia
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Recurrence
4
Breast Neoplasms
4
Blast Crisis
4
Prostatic Neoplasms
3
Neoplasms
3
Bronchiolitis Obliterans Syndrome
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Advanced Breast Cancer
2
Philadelphia Chromosome
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Indications Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancer
1
Interventions
ruxolitinib
21
Azacitidine
5
ponatinib
4
parsaclisib
4
nilotinib
4
itacitinib
4
anagrelide
3
Phlebotomy
3
Imatinib Mesylate
3
INCB039110
3
Aspirin
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
venetoclax
2
pemigatinib
2
luspatercept
2
imetelstat
2
givinostat hydrochloride
2
givinostat
2
fedratinib
2
asciminib
2
INCB057643
2
Gemcitabine
2
GRN163L peptide
2
spartalizumab
1
sonidegib
1
selinexor
1
sabatolimab
1
rucaparib
1
pembrolizumab
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myeloproliferative Disorders
×
Dasatinib
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled